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Abstract
Background: To assess progression-free survival (PFS) as the appropriate end-point for phase II
trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III
trials.
Methods: Combined data from 16 phase II studies (N = 529 patients) were analyzed to determine
progression-free survival (PFS) at 6, 9, and 12 months and the impact of age, Karnofsky
performance score (KPS), number of prior chemotherapies, and response to treatment on PFS.
Results: The specific chemotherapy used was the major effector of PFS at 6, 9, and 12 months.
Age, KPS, treatment response rate, and number of prior chemotherapies did not affect PFS to the
same extent. Hierarchical cluster analyses and linear least squares fitting of PFS9  v  PFS12
demonstrated the existence of three therapeutic efficacy groups with PFS rates at 6, 9, and 12
months ranging from lowest (A) to highest (C). The PFS6 was 15% in group A and 41% in group C
(p < .0001); the PFS12 was 9% in group A and 33% in group C (p < .0001). Further, 80% of patients
at recurrence had a 23% likelihood that each chemotherapy would provide > 1 year of additional
life.
Conclusion: Based on PFS rates at 6, 9, and 12 months for AG patients, a differential of 1.5 to 2
years is the norm and could invalidate overall survival as an end-point for phase III studies in patients
with AG. PFS is a more reliable end-point because it reflects the true antitumor benefit of the
chemotherapy.
Background
Anaplastic gliomas (AGs) constitute a group of WHO
grade III primary brain tumors that include anaplastic
astrocytoma (AA), anaplastic oligodendroglioma, [1] ana-
plastic mixed oligoastrocytoma (AOA), and anaplastic
ependymoma. [2-4] As a group, the incidence of these
tumors is approximately 1.6/100,000, which translates
into about 4400 patients who are diagnosed with the
tumor yearly in the U.S. [5,6]
AGs typically infiltrate (invade) adjacent brain. However,
in patients with the different types of AG, chemotherapy
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agents show a discrepant ability to traverse the normal
vasculature as well as tumor capillary beds and to achieve
therapeutic levels in and surrounding infiltrating tumor
cells. To date, most agents considered "active" in patients
with these tumors are lipophilic alkylating agents such as
BCNU (carmustine), CCNU (lomustine), procarbazine,
and temozolomide. [7-21] While there has been much
progress in the treatment of AG over the years, with the
median survival time seen just a few years ago going from
13 to 19 months in patients treated with surgery and irra-
diation [22,23] to 6.5 years in patients in a recent rand-
omized trial of alpha-difluoromethylornithine (DFMO,
eflornithine) plus procarbazine, CCNU, and vincristine
(PCV)  v  PCV, [24] curative treatments with reduced
regional and systemic toxicity are still very much needed.
However, one of the hindrances to the introduction of
new agents for AGs, and in particular AAs and AOAs, into
clinical use is that many of the phase II studies of single-
agent therapy and drug combinations in patients with AAs
and AOAs have shown a considerable disconnect between
the percentage of patients whose disease responds to or
stabilizes (i.e., does not progress) in response to treatment
and the durability of the treatment response, defined as
the time-to-tumor progression (TTP) or as progression-
free survival (PFS). For example, complete response (CR),
partial response (PR), minor response, and stable disease
rates of 0% to 83% have been reported, with a median
time to tumor progression (MTP) of 6 to 49 weeks and
with only a modest correlation between the rates of
response, stable disease, and MTP. [18,25-37] Thus, it is
difficult to draw firm conclusions from these studies with
regard to the effectiveness of the treatment under study.
On the basis of these and other observations, we believe
that the PFS rate at a specified time point between 6 and
12 months provides a realistic time frame for trials evalu-
ating agents for AG. That is, the use of PFS as the primary
end-point in phase II trials has the advantage of enabling
trials to be shorter in duration, plus PFS is a practical and
achievable surrogate indicator of actual long-term prog-
nosis. PFS rates at 6, 9, and 12 months (PFS6, PFS9, and
PFS12) are also good end-points, both for drugs that cause
tumor shrinkage and for those that just delay TTP.
We will demonstrate that PFS is a more realistic and accu-
rate end-point than overall survival (OS) for chemother-
apy trials of today's new agents in patients with mid- and
high-grade gliomas. [24] In this report, we will also
describe the value of PFS6, PFS9, and PFS12 and how these
end-points might be applied so that the clinical develop-
ment of effective new drugs and drug combinations can
be accelerated.
Methods
To better define whether there would be any benefit to
studying PFS6, PFS9, or PFS12 and to evaluate the impact of
age, Karnofsky performance score (KPS), and number of
prior chemotherapies on PFS, covariates typically associ-
ated with survival outcome, we collated a large retrospec-
tive database of patients with AA or AOA treated on phase
II studies. Patients with anaplastic ependymoma were
excluded because of the relative rarity of this tumor.
Patients with AOs were also excluded because these
tumors are relatively more sensitive to chemotherapy and
radiation therapy, and thus these patients should be ana-
lyzed separately from those with AA or AOA.
Data in the database were obtained from the following
sources: the same patient database used in an earlier study
[38]; reports of single-agent therapy with imatinib
(Gleevec) [39] or temozolomide [21,40]; portions of ran-
domized trials of interferon-beta v interferon-beta with
isotretinoin [38,41], carboplatin and isotretinoin [42],
and carboplatin, 5-fluorouracil, and procarbazine [43]; a
trial of DFMO performed at The University of Texas M. D.
Anderson Cancer Center (UTMDACC) and the University
of California San Francisco [37]; a published trial of temo-
zolomide and marimastat [44], and the institutional data-
base for a number of additional trials conducted at
UTMDACC and generated by Data Management Services
at UTMDACC from 1999 through 2004 [45]. The UTM-
DACC database consists of data from sequential phase II
studies. Some study findings were published only in
abstracts and others were from cooperative group studies.
In all cases, the computer database was available for inter-
rogation for these analyses. Aside from the number of pre-
vious chemotherapies, these studies had common
eligibility criteria, and one of us [39] was an investigator
in each study. The latter dataset was verified, to the extent
possible, by (a) requiring that the tumor pathology be
reviewed prior to the study by a UTMDACC neuropathol-
ogist; (b) using common MRI criteria for the determina-
tion of response and tumor progression [46]; (c)
removing patients from the analysis with biopsy and/or
strong radiological evidence of radiation necrosis [47-49];
(d) including only patients treated on phase II studies
whose full prior treatments could be fully documented;
(e) including only patients annotated evaluable in the
database; and (f) including only patients for whom full
follow up information was available. The entry require-
ments for all studies were also similar: KPSs of ≥ 60 at
study entry, unequivocal radiographic evidence of recur-
rence (progression), age ≥ 16 years, absolute neutrophil
count ≥ 1500, platelet count ≥ 125,000, and results of
chemistry and liver function tests within 1.5 to 2.0 times
the normal value, depending on the protocol. All patients
had signed an IRB-approved consent form agreeing to aBMC Cancer 2007, 7:106 http://www.biomedcentral.com/1471-2407/7/106
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formal protocol treatment and/or the use of their compu-
ter-based record.
Results
Data on patients from 16 phase II studies conducted
between 1995 and 2004 were collected. A total of 529
patients were included in the database for analysis. For all
studies and the MDACC database, complete and partial
response were determined based on the brain MRI using
the Macdonald criteria [46]. Comparison of the 16 ther-
apy groups showed no differences among the groups in
terms of age and the KPS (Table 1). Table 2 summarizes
the mean, SEM, and range for the mean age, KPS, response
(CR+PR) rates, and number of prior chemotherapy treat-
ments for each treatment group from Table 1. In addition,
t-tests for each covariate found no differences among the
16 protocols from the standpoint of patient age, KPS,
treatment response, and number of prior chemotherapies.
To better discriminate the PFS data in Table 1, we plotted
PFS6 v PFS12, PFS6 v PFS9, and PFS9 v PFS12 to determine
goodness of linear fit. The worst fit to the linear model
was seen for PFS6 v PFS12 (r2 = .64), and the best fit to the
linear model was seen for PFS9 v PFS12 (Fig. 1; r2 = .90). We
then analyzed the PFS data at 6, 9, and 12 months
together with age and KPS using hierarchical cluster anal-
yses with complete linkage and Euclidean distances (Sta-
tistica for Windows, version 5.5). This analysis yielded
three groups, which we designated A, B, and C, shown
graphically in Figure 1. The respective protocol groups,
the number of patients in the groups, and the respective
weighted mean PFS6, PFS9, and PFS12  for groups A
through C are summarized in Table 2. Of the 529 patients
in the dataset, 20% were in Group A, 65% were in Group
B, and 15% were in Group C.
From Table 3 and Figures 1 and 2, it appears that Group A
is markedly inferior to groups B and C in terms of PFS. To
test the statistical significance of this observation, we per-
formed a Cox regression analysis using covariates of age,
prior chemotherapy, and treatment group. KPS could not
be used as a covariate in this analysis since time- and
patient-coupled KPS data were incomplete. This analysis,
the results of which are summarized in Table 4, showed
that age at treatment was a significant factor (p = .006) but
that membership in treatment groups B and C was a more
significant factor, with treatment groups B and C superior
to group A from the standpoint of PFS (p < .0001).
Discussion
What are the implications of this study for phase II and
phase III chemotherapy trials? At one level, we wanted to
define what represented a "good" outcome from the
standpoint of PFS9 and PFS12. To that end, we were able to
define an indicator of efficacy in a phase II trial in AG
patients; we found that a therapy that produces a PFS6 of
≤15%, regardless of the number of prior chemotherapies,
is not likely to be worth pursuing further. Of the remain-
ing 80% of patients who made up groups B and C, PFS6
was similar for the two groups (37% vs. 41%); the PFS9
and PFS12 for the two groups, however, differed by 13%
(25% vs. 38%) and 12% 21% vs. 33%). The difference
between PFS9and PFS12 was only 4% for Group B and only
5% for Group C. Thus, for all practical purposes, we
believe clinical trial investigators can easily set the PFS bar
at 6 months or 9 months and be confident that this will
Table 1: Age, KPS, CR/PR, PFS, and prior chemotherapy regimen demographics of studiesa
Trial No. Drugs N PR/CR PFS6 PFS9 PFS12 Age (SD) KPS (SD) No. Prior Chemo 
(SD)
1 Gleevec, phase I/II [39] 22 0% 7.7% 4.8% 3.4% 46.8 (11.5) 83.2 (10.9) 1.3 (0.5)
2 DM86-15: IV carboplatin [38] 11 9% 24.9% 18.6% 6.5% 36.3 (8.6) 82.7 (10.1) 1.0 (0.0)
3 Miscellaneous agentsb [45] 32 0% 14.2% 9.8% 9.3% 40.5 (12.4) 84.2 (14.2) 2.7 (0.6)
4 Carboplatin with VP16 [42, 45] 19 5% 11.9% 10.4% 9.5% 41.3 (8.9) 85.4 (13.9) 3.0 (0.8)
5 CPT-11 alone or with thalidomide, CDDP, or tamoxifen [45] 22 9% 21.0% 15.0% 15.0% 41.3 (10.2) 80.0 (13.6) 3.0 (0.9)
6 DM92-109: interferon-beta arm [38, 41] 28 17% 20.5% 18.4% 16.7% 42.7 (9.4) 85.4 (8.8) 1.5 (1.0)
7 DM88-130: DFMO [37] 42 14% 29.1% 21.1% 19.1% 38.0 (11.2) 84.3 (11.7) 1.8 (1.2)
8 Temozolomide [40] 126 33% 46.0% 25.0% 19.6% 42.6 (11.2) 83.9 (10.8) 1.1 (0.8)
9 Temozolomide with cRA [45] 37 11% 38.6% 23.8% 20.8% 41.0 (11.4) 84.3 (14.8) 2.4 (0.7)
10 DM92-109: interferon-beta with cRA arm [38, 41] 30 7% 42.0% 28.9% 22.0% 42.5 (8.3) 84.6 (8.1) 1.5 (0.9)
11 Temozolomide [45] 56 4% 33.2% 29.3% 23.3% 39.4 (9.5) 84.6 (11.4) 2.5 (0.6)
12 cRA [45] 27 11% 29.2% 25.9% 25.9% 42.2 (12.8) 83.0 (13.0) 2.6 (0.8)
13 BCNU or CCNU alone or with 6-TG [45] 31 13% 36.4% 36.4% 27.5% 44.1 (14.4) 83.5 (11.9) 2.3 (0.5)
14 Carboplatin with cRA [45] 15 0% 44.4% 36.8% 31.5% 39.1 (9.5) 82.9 (13.8) 2.7 (0.8)
15 Temozolomide with marimastat [44] 18 7% 40.0% 38.2% 36.4% 38.6 (9.9) 88.2 (13.3) 2.2 (0.4)
16 DM89-092: carboplatin with 5-FU & procarbazine [38, 43] 13 17% 47.1% 43.9% 41.1% 43.5 (16.9.9) 81.7 (11.9) 0.9 (1.0)
aData are ordered by ascending PFS12 values.
b Thalidomide, Iressa, CI-980, etoposide, tamoxifen, Gleevec, R115577, fenretinide, topotecan, menogaril
c Only median values cited in reference.
Abbreviations: Chemo, chemotherapies; KPS, Karnofsky performance score; CR, complete response, PR, partial response; PFS, progression-free 
survival; SD, standard deviation; VP16, etoposide; CPT-11, irinotecan; CDDP, cisplatin; cRA, isotretinoin or 13-cis-retinoic acid; 5-FU, 5-fluorouracilBMC Cancer 2007, 7:106 http://www.biomedcentral.com/1471-2407/7/106
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distinguish inferior from adequate trial outcomes based
on the values in Table 3.
From our own clinical experience and the experience of
investigators in clinical phase II trials published over the
years, the value of treatment response in determining the
value of a new therapy for recurrent AGs remains prob-
lematic. Our current study supports that position, in that
the use of the overall response rate, the historical phase II
criterion, would have inadequately predicted the true ben-
efit and limitations of many of the therapies analyzed in
this study. This disconnect between the response rate and
the durability of response (see Tables 1 and 2 and Fig. 1)
is not a new concern for those conducting clinical trials in
patients with high-grade gliomas. One reason for this dis-
connect is undoubtedly the limited antitumor activity of
today's chemotherapy agents. Another reason proposed in
the past is that the central nervous system does not rapidly
remove dead glioma tumor cells. [50] Thus, the time
before tumor cell kill can be visualized may be considera-
bly delayed and lost in the process of a clinical follow up,
unless meticulously sought. [51] This makes it difficult to
pinpoint the actual rate or durability of response.
Furthermore, there is a mistaken belief that determining
response is easier than determining tumor progression in
patients with AG, but also that response is the only true
indicator of drug effect for phase II trials. Historically,
however, determining a response has frequently been
more difficult than determining tumor progression (treat-
ment failure). [49] This becomes even more of a problem,
however, when pharmaceutical companies insist that
patients not be entered into phase II trials until their ini-
tial therapy has failed, which for patients with AG could
be the time it takes to develop postoperative gliosis or a
radiation effect. Such a practice has the potential to lead
to a disturbing false-positive response rate because the
effectiveness of treatment is based on the resolution of
postoperative changes and not the effects of treatment.
While the same could be said for defining tumor progres-
sion in the face of radiation effects, the definition of ther-
apeutic failure appears to be more reliable. [46,52] Hence,
it is the current belief of many clinical trial neuro-oncolo-
gists that PFS is a much better indicator of treatment effi-
cacy than the response rate. Certainly it is our hope that
future therapies will be so effective that complete
responses will be seen regularly and the therapeutic bar
will be raised even higher, but until that time, it is impor-
tant to consider PFS a legitimate measure for studies of
single agents and drug combinations for the purpose of
community usage but also, in some cases, for marketing
approval.
How treatment-defining phase III clinical chemotherapy
trials for patients with malignant gliomas are designed
and conducted is a concern. Currently, OS is considered
Table 3: Weighted PFS values for the three clusters (groups)*
Groups Trial No. N PFS6 PFS9 PFS12
A 1–5 106 15% 11% 9%
B 6–12 346 37% 25% 21%
C 13–16 77 41% 38% 33%
B+C 6–16 423 38% 27% 23%
* Groups are shown in Figure 1, and the values were calculated from 
data in trials summarized in Table 1.
PFS for groups B+C are weighted means of averages shown for groups 
B and C.
Table 2: The mean, SEM, and range of ages, KPS, response (PR/CR), and number of prior chemotherapies for the 16 groups*
Age KPS PR+CR Number of prior chemotherapies
012 ≥ 3
Mean 41 84 10% 2.5% 52% 34% 9%
SEM 0.7 0.5 2.2 1.8 6.0 4.7 2.3
Group ranges 36–47 80–88 0–33 0–24 10–100 0–69 0–26
*T-test comparisons for all variables among the 16 groups were not significantly different. KPS = Karnofsky performance score; PR = partial 
response; CR = complete response.
Linear regression plots of the treatment pairs PFS9 versus  PFS12 Figure 1
Linear regression plots of the treatment pairs PFS9 versus 
PFS12. Circled areas A, B, and C are regions coincidental with 
the clusters yielded by the hierarchical cluster analysis.BMC Cancer 2007, 7:106 http://www.biomedcentral.com/1471-2407/7/106
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the benchmark for assessing the benefit of new chemo-
therapy, radiotherapy, or chemoradiation regimens in
phase III trials conducted in patients with glioblastomas
(WHO grade 4). This end-point is reasonable and accept-
able in this setting at this time, since, for the most part, the
Kaplan-Meier probability of surviving declines exponen-
tially and survival in patients treated with current agents
minimally deviates from this expectation. In phase III tri-
als in patients with AG, however, OS is arguably the
wrong study end-point. This is because, as shown in Table
3, there are a number of chemotherapy treatments that
can significantly prolong life after first tumor progression
and thereby lengthen OS, independently of the phase III
trial regimen being tested. For example, by extrapolating
from Table 3, one could predict that 80% of patients in
our phase II studies have, on average, a 23% (21% to
33%) chance of living more than 1 year for each treatment
protocol they receive. How, then, might this impact the
interpretation of a recent randomized phase III study of
an effective agent?
To answer this question, we examined our findings from
the current study of PFS in phase II studies in light of the
results from the recent phase III randomized trial of
DFMO-PCV v PCV alone for patients with AG tumors.
[24] In that study, there was a marked difference in the
median PFS between the two treatment arms, but there
was far less of a difference in the median OS between the
two treatment arms. [24] In particular, the median PFS
was 71 months and the median OS was 76 months in the
DFMO-PCV group, but the median PFS was only 38
months while the median OS was 61 months in the PCV
group. We reviewed this study in May 2006 to determine
how many patients had had disease progression and what
treatment options they had then elected. We found that
46% of the DFMO-PCV patients and 41% of the PCV
patients had been censored during the 13 years since
study inception. Furthermore, among non-censored
patients, we found that 34% of patients received an aver-
age of 1.6 chemotherapies after tumor progression, 22%
underwent 1.1 further surgeries, 3% underwent 1.0 re-
irradiation, and 15% of patients were treated with more
than one modality. Thus, no matter how careful the rand-
omization, one could not account prospectively for the
fact that one group required more therapies at recurrence
than did the other group. The fact that a number of con-
temporary phase II trials of chemotherapies for AGs pro-
duce substantial palliation (21% to 33% PFS12) means
that OS as an end-point would not truly reflect the benefit
of the primary phase III regimen. In the case of the DFMO-
PCV trial discussed above, only 23 months (OS – PFS) of
successful phase II chemotherapies would have been
needed. In addition, in the cited example above, reopera-
tion and repeat irradiation were also used after tumor pro-
gression.
For these reasons, we strongly question whether phase III
studies with OS as the primary end-point can or should be
conducted in patients with AGs at this time. We argue that
OS as an end-point for phase III AG studies today is a
flawed objective and that its use will result in new and
effective regimens tested in phase III trials being judged
ineffective (false negative) for the treatment of AG.
Conclusion
We conclude from our analysis that PFS is a much more
valuable and reliable end-point for phase III studies than
overall survival, because it reflects the true antitumor ben-
efit of the chemotherapy being studied. Since the median
survival of AG patients can range from 4 to 6 years, focus-
ing on PFS in phase III studies would also allow studies to
be performed and concluded in possibly half that time. It
is hoped that this article will help to convince clinical trial
investigators, the pharmaceutical industry, and govern-
ment regulators to develop robust strategies that utilize
This is the Kaplan-Meier plot of the probability of PFS for  patients from Groups A, B, and C Figure 2
This is the Kaplan-Meier plot of the probability of PFS for 
patients from Groups A, B, and C.
Table 4: Results of Cox regression analysis*
Covariate Hazard function** (95% 
confidence intervals)
p-value
Age 1.01 (1.00, 1.02) .006
Prior chemotherapy 1.02 (0.92, 1.14) .659
Group B 0.48 (0.35, 0.66) <.0001
Group C 0.51 (0.40, 0.65) <.0001
*Analysis was performed using treatment groups A through C as a 
categorical indicator and Group A as the reference.
**Hazard function if less than 1 it indicates increased PFS and, if 
greater than 1 decreased PFS. In the case above, Groups B+C are 
associated with statistically increased PFS.BMC Cancer 2007, 7:106 http://www.biomedcentral.com/1471-2407/7/106
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PFS as the primary end-point in trials of much-needed
therapies for patients with AGs.
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